Inhibition of vaccinia virus replication by peptide aptamers

Antiviral Research

Volumn 82, Issue 3, 2009, Pages 134-140

  Saccucci, Laurent ^a,b   Crance, Jean Marc ^a   Colas, Pierre ^c   Bickle, Marc ^c   Garin, Daniel ^a   Iseni, Frédéric ^a  

^a CRSSA Emile Parde   (France)

^b Protein'eXpert SA   (France)

^c Aptanomics   (France)

Author keywords

Anti orthopoxvirus drugs; Genetic screen; Peptide aptamer; Vaccinia virus; Yeast two hybrid

Indexed keywords

GLUTATHIONE TRANSFERASE; PEPTIDE APTAMER; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS PROTEIN; VIRUS PROTEIN A20;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BINDING SITE; COMBINATORIAL LIBRARY; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG PROTEIN BINDING; DRUG SCREENING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; VACCINIA VIRUS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; APTAMERS, PEPTIDE; CELL LINE; DNA, VIRAL; HUMANS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; TWO-HYBRID SYSTEM TECHNIQUES; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

ORTHOPOXVIRUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 64749114482     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.02.191     Document Type: Article

References (37)

1. Abed N., Bickle M., Mari B., Schapira M., Sanjuan-Espana R., Robbe Sermesant K., Moncorgé O., Mouradian-Garcia S., Barbry P., Rudkin B.B., Fauvarque M.O., Michaud-Soret I., and Colas P. A comparative analysis of perturbations caused by a gene knock-out, a dominant negative allele, and a set of peptide aptamers. Mol. Cell. Proteomics 6 (2007) 2110-2121
2. Andrei G., Gammon D.B., Fiten P., De Clercq E., Opdenakker G., Snoeck R., and Evans D.H. Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice. J. Virol. 80 (2006) 9391-9401
3. Baines I.C., and Colas P. Peptide aptamers as guides for small-molecule drug discovery. Drug Discov. Today 11 (2006) 334-341
4. Bickle M.B., Dusserre E., Moncorgé O., Bottin H., and Colas P. Selection and characterization of large collections of peptide aptamers through optimized yeast two-hybrid procedures. Nat. Protoc. 1 (2006) 1066-1091
5. Blasco R., and Moss B. Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein. J. Virol. 65 (1991) 5910-5920
6. Borghouts C., Kunz C., Delis N., and Groner B. Monomeric recombinant peptide aptamers are required for efficient intracellular uptake and target inhibition. Mol. Cancer Res. 6 (2008) 267-281
7. Boyle K.A., Arps L., and Traktman P. Biochemical and genetic analysis of the vaccinia virus d5 protein: multimerization-dependent ATPase activity is required to support viral DNA replication. J. Virol. 81 (2007) 844-859
8. Butz K., Denk C., Fitscher B., Crnkovic-Mertens I., Ullmann A., Schröder C.H., and Hoppe-Seyler F. Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20 (2001) 6579-6586
9. Butz K., Denk C., Ullmann A., Scheffner M., and Hoppe-Seyler F. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 6693-6697
10. Colas P. The eleven-year switch of peptide aptamers. J. Biol. 7 (2008) 2
11. Colas P., Cohen B., Jessen T., Grishina I., McCoy J., and Brent R. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. Nature 380 (1996) 548-550
12. Colas P., Cohen B., Ko Ferrigno P., Silver P.A., and Brent R. Targeted modification and transportation of cellular proteins. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 13720-13725
13. Cresawn S.G., and Condit R.C. A targeted approach to identification of vaccinia virus postreplicative transcription elongation factors: genetic evidence for a role of the H5R gene in vaccinia transcription. Virology 363 (2007) 333-341
14. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16 (2003) 569-596
15. De Silva F.S., Lewis W., Berglund P., Koonin E.V., and Moss B. Poxvirus DNA primase. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 18724-18729
16. Ferrier A., Garin D., and Crance J.M. Rapid inactivation of vaccinia virus in suspension and dried on surfaces. J. Hosp. Infect. 57 (2004) 73-79
17. Geddes A.M. The history of smallpox. Clin. Dermatol. 24 (2006) 152-157
18. Geyer C.R., and Brent R. Selection of genetic agents from random peptide aptamer expression libraries. Methods Enzymol. 328 (2000) 171-208
19. Hoppe-Seyler F., Crnkovic-Mertens I., Tomai E., and Butz K. Peptide aptamers: specific inhibitors of protein function. Curr. Mol. Med. 4 (2004) 529-538
20. Ishii K., and Moss B. Role of vaccinia virus A20R protein in DNA replication: construction and characterization of temperature-sensitive mutants. J. Virol. 75 (2001) 1656-1663
21. Ishii K., and Moss B. Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex. Virology 303 (2002) 232-239
22. Klemperer N., McDonald W., Boyle K., Unger B., and Traktman P. The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase. J. Virol. 75 (2001) 12298-12307
23. Kornbluth R.S., Smee D.F., Sidwell R.W., Snarsky V., Evans D.H., and Hostetler K.Y. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob. Agents Chemother. 50 (2006) 4038-4043
24. Lane H.C., Montagne J.L., and Fauci A.S. Bioterrorism: a clear and present danger. Nat. Med. 7 (2001) 1271-1273
25. Lopez-Ochoa L., Ramirez-Prado J., and Hanley-Bowdoin L. Peptide aptamers that bind to a geminivirus replication protein interfere with viral replication in plant cells. J. Virol. 80 (2006) 5841-5853
26. Mathew A., Terajima M., West K., Green S., Rothman A.L., Ennis F.A., and Kennedy J.S. Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles. J. Immunol. 174 (2005) 2212-2219
27. McCraith S., Holtzman T., Moss B., and Fields S. Genome-wide analysis of vaccinia virus protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 4879-4884
28. Moss B. Poxviridae: The viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology vol. 2 (2007), Lippincott, Williams, & Wilkins, Philadelphia 2905-2945 (2 vols.)
29. Nauenburg S., Zwerschke W., and Jansen-Durr P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 15 (2001) 592-594
30. Pamonsinlapatham P., Hadj-Slimane R., Raynaud F., Bickle M., Corneloup C., Barthelaix A., Lepelletier Y., Mercier P., Schapira M., Samson J., Mathieu A.L., Hugo N., Moncorgé O., Mikaelian I., Dufour S., Garbay C., and Colas P. A RasGAP SH3 peptide aptamer inhibits RasGAP-Aurora interaction and induces caspase-independent tumor cell death. PLoS ONE 3 (2008) e2902
31. Parker S., Touchette E., Oberle C., Almond M., Robertson A., Trost L.C., Lampert B., Painter G., and Buller R.M. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model. Antivir. Res. 77 (2008) 39-49
32. Punjabi A., Boyle K., DeMasi J., Grubisha O., Unger B., Khanna M., and Traktman P. Clustered charge-to-alanine mutagenesis of the vaccinia virus A20 gene: temperature-sensitive mutants have a DNA-minus phenotype and are defective in the production of processive DNA polymerase activity. J. Virol. 75 (2001) 12308-12318
33. Scaramozzino N., Ferrier-Rembert A., Favier A.L., Rothlisberger C., Richard S., Crance J.M., Meyer H., and Garin D. Real-time PCR to identify variola virus or other human pathogenic orthopox viruses. Clin. Chem. 53 (2007) 606-613
34. Smee D.F., Sidwell R.W., Kefauver D., Bray M., and Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46 (2002) 1329-1335
35. Stanitsa E.S., Arps L., and Traktman P. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase. J. Biol. Chem. 281 (2006) 3439-3451
36. Traktman P., Anderson M.K., and Rempel R.E. Vaccinia virus encodes an essential gene with strong homology to protein kinases. J. Biol. Chem. 264 (1989) 21458-21461
37. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., De Clercq E., Jones K., Hruby D., and Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 79 (2005) 13139-13149